股本结构
单位：万股
| 公告日期 | 2026-10-09 | 2026-05-22 | 2026-03-26 | 2026-01-22 | 2026-01-08 | 2026-03-26 |
|---|---|---|---|---|---|---|
| 证券总股本 | 495.52 | 402.21 | 402.21 | 283.53 | 280.98 | 266.01 |
| 普通股本 | 495.52 | 402.21 | 402.21 | 283.53 | 280.98 | 266.01 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-10-09 | 2026-05-21 | 2026-03-01 | 2026-01-14 | 2026-01-07 | 2025-12-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-10-09 | 495.52 | 未披露 | 定期报告 | 2026-10-09 |
| 2026-05-22 | 402.21 | 未披露 | 定期报告 | 2026-05-21 |
| 2026-03-26 | 402.21 | 未披露 | 定期报告 | 2026-03-01 |
| 2026-01-22 | 283.53 | 未披露 | 定期报告 | 2026-01-14 |
| 2026-01-08 | 280.98 | 未披露 | 定期报告 | 2026-01-07 |
| 2026-03-26 | 266.01 | 未披露 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of Common Stock and warrants from January 2025 PIPE, net of issuance costs
Issuance of Common Stock upon exercise of pre-funded warrants
Issuance of Common Stock and warrants from March 2025 Warrant Inducement, net of issuance costs
Issuance of Common Stock and warrants from December 2025 PIPE, net of issuance costs
Issuance of Common Stock from ATM sales, net of issuance costs
|
2025-12-31 |
| 2025-12-29 | 117.58 | 未披露 | 定期报告 | 2025-12-29 |
| 2025-11-14 | 102.65 | 未披露 | 定期报告 | 2025-11-12 |
| 2025-11-14 | 84.45 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of abeyance shares
|
2025-09-30 |
| 2025-08-13 | 68.16 | 未披露 | 定期报告 | 2025-08-11 |
| 2025-07-30 | 63.78 | 未披露 |
更多>>
a one-for-10 reverse stock split of the Company's issued and outstanding shares of common stock
|
2025-08-01 |
| 2025-05-14 | 637.81 | 未披露 | 定期报告 | 2025-05-12 |
| 2025-05-14 | 603.26 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of Common Stock and warrants from January 2025 PIPE, net of issuance costs
Issuance of Common Stock upon exercise of pre-funded warrants
Issuance of Common Stock and warrants from March 2025 Warrant Inducement, net of issuance costs
|
2025-03-31 |
| 2025-03-17 | 543.06 | 未披露 | 定期报告 | 2025-03-01 |
| 2025-01-30 | 535.82 | 未披露 | 定期报告 | 2025-01-24 |
| 2025-01-23 | 502.32 | 未披露 | 定期报告 | 2025-01-23 |
| 2025-03-17 | 251.78 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of abeyance shares
Issuance of Common Stock and warrants from May 2024 Warrant Inducement
Issuance of abeyance shares from warrant inducement
Issuance of Common Stock from ATM sales, net of issuance costs
Issuance of Common Stock upon exercise of pre-funded warrants
Settlement of fractional shares paid in cash
|
2024-12-31 |
| 2024-11-13 | 204.08 | 未披露 | 定期报告 | 2024-11-12 |
| 2024-11-13 | 167.78 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of Common Stock upon exercise of pre-funded warrants
Issuance of Common Stock from ATM sales, net of issuance costs
Issuance of abeyance shares
|
2024-09-30 |
| 2024-09-19 | 151.02 | 未披露 | 定期报告 | 2024-09-17 |
| 2024-08-07 | 131.60 | 未披露 | 定期报告 | 2024-08-05 |
| 2024-07-15 | 69.32 | 未披露 | 定期报告 | 2024-07-01 |
| 2024-08-07 | 69.32 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of Common Stock upon exercise of warrants, net of issuance costs
Settlement of fractional shares paid in cash
|
2024-06-30 |
| 2024-06-07 | 56.22 | 未披露 | 定期报告 | 2024-05-31 |
| 2024-05-15 | 44.41 | 未披露 |
更多>>
a one-for-fifteen reverse stock split of the Company’s issued and outstanding shares of Common Stock
|
2024-05-16 |
| 2024-03-21 | 666.08 | 未披露 | 定期报告 | 2024-03-18 |
| 2024-03-21 | 393.08 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of Common Stock upon exercise of warrants, net of issuance costs
Issuance of Common Stock and warrants, net of issuance costs
Issuance of Common Stock upon exercise of pre-funded warrants
Settlement of fractional shares paid in cash
|
2023-12-31 |
| 2023-12-07 | 353.90 | 未披露 | 定期报告 | 2023-11-29 |
| 2023-07-07 | 318.90 | 未披露 | 定期报告 | 2023-07-06 |
| 2023-06-23 | 318.90 | 未披露 | 定期报告 | 2023-06-05 |
| 2023-05-25 | 284.67 | 未披露 |
更多>>
Common Stock offered by the company 458,555 shares
|
2023-05-26 |
| 2023-05-25 | 238.82 | 未披露 | 定期报告 | 2023-05-23 |
| 2023-05-11 | 233.82 | 未披露 | 定期报告 | 2023-05-10 |
| 2023-05-11 | 238.82 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common stock and warrants, net of issuance costs
Issuance of common stock upon exercise of pre-funded warrants
Settlement of fractional shares paid in cash
|
2023-03-31 |
| 2023-03-20 | 85.51 | 未披露 |
更多>>
Common Stock offered 85,000 shares by the company
|
2023-03-20 |
| 2023-03-13 | 77.01 | 未披露 |
更多>>
On March 13, 2023, Dermata Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time, on March 14, 2023, a 1-for-16 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).
|
2023-03-14 |
| 2023-01-13 | 1232.18 | 未披露 | 定期报告 | 2022-12-28 |
| 2022-11-15 | 1210.22 | 未披露 | 定期报告 | 2022-11-11 |
| 2022-11-10 | 1210.22 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock upon exercise of pre-funded warrants
|
2022-09-30 |
| 2022-08-15 | 1010.22 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock and warrants, net of issuance costs
Issuance of common stock upon exercise of pre-funded warrants
|
2022-06-30 |
| 2022-05-16 | 922.72 | 未披露 | 定期报告 | 2022-05-13 |
| 2022-05-04 | 1587.58 | 未披露 | 定期报告 | 2022-04-22 |
| 2022-05-04 | 922.72 | 未披露 | 定期报告 | 2022-04-20 |
| 2021-08-16 | 832.86 | 未披露 |
更多>>
1.Units being offered 2,571,428 Units
2.The number of shares of common stock to be outstanding immediately after this offering is based on 5,757,201 shares of common stock outstanding as of August 12, 2021
|
2021-08-13 |
From December 31, 2024 to December 31, 2025
Issuance of Common Stock and warrants from January 2025 PIPE, net of issuance costs
Issuance of Common Stock upon exercise of pre-funded warrants
Issuance of Common Stock and warrants from March 2025 Warrant Inducement, net of issuance costs
Issuance of Common Stock and warrants from December 2025 PIPE, net of issuance costs
Issuance of Common Stock from ATM sales, net of issuance costs
From June 30, 2025 to September 30, 2025
Issuance of abeyance shares
a one-for-10 reverse stock split of the Company's issued and outstanding shares of common stock
From December 31, 2024 to March 31, 2025
Issuance of Common Stock and warrants from January 2025 PIPE, net of issuance costs
Issuance of Common Stock upon exercise of pre-funded warrants
Issuance of Common Stock and warrants from March 2025 Warrant Inducement, net of issuance costs
From December 31, 2023 to December 31, 2024
Issuance of abeyance shares
Issuance of Common Stock and warrants from May 2024 Warrant Inducement
Issuance of abeyance shares from warrant inducement
Issuance of Common Stock from ATM sales, net of issuance costs
Issuance of Common Stock upon exercise of pre-funded warrants
Settlement of fractional shares paid in cash
From June 30, 2024 to September 30, 2024
Issuance of Common Stock upon exercise of pre-funded warrants
Issuance of Common Stock from ATM sales, net of issuance costs
Issuance of abeyance shares
From March 31, 2024 to June 30, 2024
Issuance of Common Stock upon exercise of warrants, net of issuance costs
Settlement of fractional shares paid in cash
a one-for-fifteen reverse stock split of the Company’s issued and outstanding shares of Common Stock
From December 31, 2022 to December 31, 2023
Issuance of Common Stock upon exercise of warrants, net of issuance costs
Issuance of Common Stock and warrants, net of issuance costs
Issuance of Common Stock upon exercise of pre-funded warrants
Settlement of fractional shares paid in cash
Common Stock offered by the company 458,555 shares
From December 31, 2022 to March 31, 2023
Issuance of common stock and warrants, net of issuance costs
Issuance of common stock upon exercise of pre-funded warrants
Settlement of fractional shares paid in cash
Common Stock offered 85,000 shares by the company
On March 13, 2023, Dermata Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time, on March 14, 2023, a 1-for-16 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).
From June 30, 2022 to September 30, 2022
Issuance of common stock upon exercise of pre-funded warrants
From March 31, 2022 to June 30, 2022
Issuance of common stock and warrants, net of issuance costs
Issuance of common stock upon exercise of pre-funded warrants
1.Units being offered 2,571,428 Units
2.The number of shares of common stock to be outstanding immediately after this offering is based on 5,757,201 shares of common stock outstanding as of August 12, 2021